Sampo plc
SAMPO PLC MANAGERS’ TRANSACTIONS 3 March 2021 at 11:50 am
Sampo plc: Managers’ Transactions (Tetrao SA)
Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation.
____________________________________________
Person subject to the notification requirement
Name: Tetrao SA
Position: Closely associated person
(X) Legal person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Björn Wahlroos
Position: Member of the Board
Issuer: Sampo plc
LEI: 743700UF3RL386WIDA22
Notification type: INITIAL NOTIFICATION
Reference number: 743700UF3RL386WIDA22_20210303083839_5
____________________________________________
Transaction date: 2021-03-02
Venue not applicable
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
ISIN: XS1995716211
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 5,000,000 Unit price: 1.144 EUR
(2): Volume: 5,000,000 Unit price: 1.144 EUR
Aggregated transactions
(2): Volume: 10,000,000 Volume weighted average price: 1.144 EUR
____________________________________________
Transaction date: 2021-03-01
Venue not applicable
Instrument type: DEBT INSTRUMENT
ISIN: XS2226645278
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 3,000,000 Unit price: 1.055
Aggregated transactions
(1): Volume: 3,000,000 Volume weighted average price: 1.055
SAMPO PLC
Jarmo Salonen
Head of Investor Relations and Group Communications
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
London Stock Exchange
Financial Supervisory Authority
The principal media
www.sampo.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom